Eurofarma
Carlos E. Carelli Jr. has extensive experience in analytical development and preformulation, currently serving as the Analytical Development Manager at Eurofarma since September 2016. Prior to this role, Carlos held positions at Blanver and Eurofarma, where responsibilities included managing the preformulation lab and overseeing drug master file teams. Carlos began a career in the pharmaceutical industry as a QC Analyst at ABL - Antibióticos do Brasil Ltda., and also worked as a Preformulation Researcher at EMS, focusing on method development and raw material analysis. Academic credentials include an MBA from FGV - Fundação Getulio Vargas, a Drug Development extension at the University of Wisconsin-Madison, and a degree in Chemistry from USP - Universidade de São Paulo.
This person is not in any teams
This person is not in any offices
Eurofarma
5 followers
Since its establishment in 1972, Eurofarma has been operating in the health industry, producing and marketing products and services to improve people's quality of life. Focused on generating shared value, it operates in the areas of Prescription, Nos-Prescription, Generics, Hospital and Oncology. It offers over 700 products, over 2,000 SKUs and serves 42 medical specialties. In Brazil, it covers 100 therapeutic classes, which represent 70% of prescriptions in the entire market. Operating in 20 countries, with manufacturing facilities in Brazil and industrial parks in six other Latin American countries, it generated net sales of R$ 7.1 billion in 2021, a growth of 23% compared to the previous year, and employs more than 8,100 people.